Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Progress has been astonishing, but the need for personalized care can only be addressed through a universal focus on diversity and equity in rheumatology research.
Both rheumatology and the publishing environment have seen tremendous changes over the past two decades. Here, the first Editor in-Chief reflects on the challenges faced by this journal and what it has taken to remain at the forefront of the field.
The future of rheumatology research will be defined by the growing era of personalized and stratified medicine, with a focus on establishing drug-free remission. In the face of substantial global upheaval, now is the time to ensure no patient group is left behind by prioritizing research equity and inclusion.
In the past two decades the field of hand osteoarthritis (OA) has moved from resignation to action. Despite progress, such as the recognition of the phenotypic heterogeneity of hand OA (including inflammation- and/or metabolic syndrome-associated hand OA) and the standardization of imaging and treatment outcomes, challenges remain in achieving truly disease-modifying therapies.
The collective priorities of the rheumatology field represent the lived experience, and therefore diversity of its members. The ‘mould’ of rheumatology, that is, its culture, structures and expectations, was not created for or by women, but women have slowly changed this mould to make space for diverse perspectives.
Although DADA2 is typically described as an autosomal recessive disease, it can also present in individuals who are heterozygous for specific ADA2 variants.
In this Review article, the potential of cytometry- and single-cell RNA sequencing-based immune profiling for aiding the diagnosis and personalized treatment of rheumatic diseases is discussed.
Evidence is emerging that glucagon-like peptide-1 (GLP-1) receptor agonists have anti-inflammatory and chondroprotective properties independent of their effects on weight loss. In this Review, the authors discuss the potential effects of GLP-1 receptor agonists on the incidence, disease activity and progression of various forms of arthritis, as well as practical considerations for their use in this context.
This Perspective article discusses the stratification of patients with knee osteoarthritis (OA) in the context of current guidelines, biomarkers and emerging and future developments of targeted treatment. The authors aim to highlight how these novel developments can enhance the stratification of patients with knee OA to improve patient outcomes.
